/

Empresas

Ag

No verificado

Agendia, Inc.

Sobre qué escribimos

BiotecnologíaCienciaIndustriaOncologíaSalud

19 Comunicados de prensa

Ver todos los comunicados de prensa

31/03/2026

Industria

Salud

Oncología

Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Fuente

Editor

1.00

0

12/08/2025

Ciencia

VIH, SIDA y enfermedades autoinmunes

Biotecnología

Sanidad

Salud

Oncología

Análisis de Mercados

Industria

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

Fuente

Editor

1.00

0

27/05/2025

Eventos

Ciencia

Biotecnología

Medicina - Varios

Salud

Sanidad

Oncología

Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO® Annual Meeting

Fuente

Editor

1.00

0

15/05/2025

Eventos

Ciencia

Material médico sanitario

Biotecnología

Medicina - Varios

Salud

Oncología

Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting

Fuente

Editor

1.00

0

06/05/2025

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

Fuente

Editor

1.00

0

24/04/2025

Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting

Fuente

Editor

1.00

0

11/02/2025

Ampliata l'indicazione di rimborso di MammaPrint® in Belgio

Fuente

Editor

1.00

0

11/02/2025

MammaPrint® Reimbursement Indication Extended in Belgium

Fuente

Editor

1.00

0

09/01/2025

Agendia, Inc. presenta un'analisi di un 2024 coronato dal successo

Fuente

Editor

1.00

0

09/01/2025

Agendia, Inc. Provides Review of Successful 2024

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0